STOCKSCOPE

Capricorn Metals (ASX: CMM): High-Grade Gold Hits Raise the Stakes at Mt Gibson

Alison Elzayed

Alison Elzayed

Business & Finance Writer | StockScope

Published:26 Oct 2026
Capricorn Metals (ASX: CMM): High-Grade Gold Hits Raise the Stakes at Mt Gibson

Capricorn Metals has delivered some striking gold intercepts at its Mt Gibson Gold Project, but the bigger question is whether these results can translate into a second major production engine. The timing is notable: shares closed at $12.39 on 23 October, down about 14% from $14.42 a week earlier. We think the latest drilling deserves attention because it could help shape Capricorn’s longer-term growth beyond its established Karlawinda operation.

The numbers tell an intriguing story

  • 6.0 metres at 57.38 grams per tonne (g/t) gold: a high-grade Lexington intercept.
  • 7.0 metres at 40.01g/t gold: another substantial high-grade result.
  • 29.5 metres at 6.65g/t gold: a wider mineralised interval at Lexington.
  • 3.0 metres at 89.88g/t gold: an intercept at Hornet beneath the current reserve pit.
  • $535 million: cash and gold held at the end of September 2026.

The discovery could be bigger than one drill result

The 26 October update reported further high-grade results from Lexington, one of several advanced underground prospects at Mt Gibson. Drilling is testing mineralisation beyond existing open-pit and underground reserve designs, creating the potential to expand the project's mineable inventory.

The distinction matters. High grades can improve potential project economics, but individual intercepts do not establish the size, continuity or commercial viability of an orebody. Capricorn still needs sufficient drilling, geological modelling and resource estimation to demonstrate whether these zones can support sustainable underground mining.

A strong producer with room to expand

Capricorn's existing business provides a substantial financial foundation. In FY26, revenue reached $769.3 million, underlying net profit after tax rose 59% to $327.2 million, and operating cash flow climbed 81% to $470.2 million. Its September quarter ended with $535 million in cash and gold, following continued investment in growth projects.

The company is also expanding Karlawinda. Its completed expansion is designed to lift processing capacity to 6.5 million tonnes annually and support production of about 150,000 ounces of gold a year once fully ramped up. That creates a separate growth pathway while Mt Gibson advances.

What could strengthen or weaken the case?

Capricorn has two important advantages: an operating mine generating cash and a substantial balance sheet to fund development. However, FY27 production guidance remains 137,000 to 147,000 ounces, with all-in sustaining costs of $1,900 to $2,100 an ounce. Costs have increased from FY26's $1,629 an ounce, making execution and realised gold prices important to profitability.

Valuation also matters. At $12.39, Capricorn's market capitalisation was approximately $5.7 billion, implying about 17 times FY26 underlying earnings. That is not an obviously low valuation, particularly when the Mt Gibson growth opportunity still requires development and execution.

Insight: Can Mt Gibson justify today's valuation?

Our view is that Capricorn's appeal lies in the combination of current cash generation and potential future production, rather than any single spectacular drill result. The high-grade intercepts strengthen the geological story, but the real value depends on whether drilling establishes a sufficiently large, continuous and economically mineable underground resource. We would place greater weight on the forthcoming resource estimate and development economics than on headline grades alone. If those milestones validate a second production centre, the longer-term growth case becomes more tangible.

The next milestone matters most

Capricorn plans to continue drilling at Lexington, Hornet and Orion South, with a maiden underground resource estimate for Lexington targeted for later in the December 2026 quarter. Further results should help clarify the scale and continuity of mineralisation.

The key question is whether Mt Gibson can evolve from a promising exploration project into a commercially credible second mine, while Karlawinda delivers its planned expansion. That distinction will determine how much of Capricorn's growth potential can ultimately translate into sustainable cash flow.

Alison Elzayed

Alison Elzayed

(Business & Finance Writer | StockScope)

Alison Elzayed is an experienced business and financial writer with more than 10 years of experience in the publishing industry, having previously worked as an author with Bloomsbury Publishing, specialising in business and finance. Throughout her career, Alison has developed a strong understanding of financial markets, corporate developments, economic trends and investment-related topics. Her background in financial publishing has equipped her with the ability to research complex subjects and communicate them in a clear, accurate and engaging manner.

DisclaimerInformation on Stockscope is general in nature and does not constitute financial product advice. It does not take into account your personal objectives, financial situation or needs. Seek independent advice from a qualified financial adviser before making an investment decision. Stockscope and its affiliates do not guarantee the accuracy or completeness of information published on this website. To the extent permitted by law, they accept no liability for any claim, loss or damage arising from its use or reliance on it. Stockscope and its associates may have commercial relationships with companies featured on this website, hold securities in those companies, or receive commissions in connection with capital raisings.

Continue Reading

ASX Weathers Wall Street's AI Rout, but Three Market Risks Are Becoming Harder to Ignore
Market Briefings
Market Briefings

ASX Weathers Wall Street's AI Rout, but Three Market Risks Are Becoming Harder to Ignore

Australian equities: what moved the ASX 200? Australian shares finished lower on Friday, 6 November, as the technology-led sell-off on Wall Street spread across global markets. The ASX 200...

Mark ElzayedMark Elzayed•
Epiminder (ASX: EPI) Expands FDA Clearance as $65 Million Cash Reserve Faces a Crucial Commercial Test
Biotech & Health
Biotech & Health

Epiminder (ASX: EPI) Expands FDA Clearance as $65 Million Cash Reserve Faces a Crucial Commercial Test

Epiminder Limited ASX: EPI has expanded the US market for its epilepsy monitoring technology following a significant regulatory clearance, strengthening its commercial prospects ahead of a p...

Danny AadDanny Aad•
Asara Resources (ASX: AS1) Hits 38m at 2.1g/t Gold: Could Sogosogoba Unlock Kada's Next Growth Phase?
Mining
Mining

Asara Resources (ASX: AS1) Hits 38m at 2.1g/t Gold: Could Sogosogoba Unlock Kada's Next Growth Phase?

A 38-metre gold intersection grading 2.1 grams per tonne has given Asara Resources Limited ASX: AS1 an encouraging exploration result beyond its established Massan deposit in Guinea. The dis...

Alison ElzayedAlison Elzayed•
Alvo Minerals (ASX: ALV) Expands Rare Earth Discovery Across 6.5km², but Can It Deliver Economic Value?
Mining
Mining

Alvo Minerals (ASX: ALV) Expands Rare Earth Discovery Across 6.5km², but Can It Deliver Economic Value?

Alvo Minerals Limited ASX: ALV has extended rare earth mineralisation approximately 2 kilometres beyond previously tested areas at its Boa Vista prospect in Brazil, strengthening the explora...

Alison ElzayedAlison Elzayed•
Avenira Limited (ASX: AEV) Raises $48.9 Million as Wonarah Phosphate Project Faces Its Biggest Test Yet
Mining
Mining

Avenira Limited (ASX: AEV) Raises $48.9 Million as Wonarah Phosphate Project Faces Its Biggest Test Yet

Avenira Limited ASX: AEV has reached a significant financing milestone, with its $48.9 million rights issue providing fresh capital to advance the Wonarah Phosphate Project in the Northern T...

Alison ElzayedAlison Elzayed•
Mayne Pharma Group (ASX: MYX) Unveils $55.5 Million Sale, but Can Its US Business Deliver Stronger Profits?
Biotech & Health
Biotech & Health

Mayne Pharma Group (ASX: MYX) Unveils $55.5 Million Sale, but Can Its US Business Deliver Stronger Profits?

Mayne Pharma Group Limited ASX: MYX is taking a decisive step towards becoming a US-focused pharmaceutical company, agreeing to sell its international operations for $55.5 million. The tran...

Danny AadDanny Aad•
Loading more stories...